Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Mild to moderate hypertension (adjunctive therapy),Psychotic disorders (off-label),Tardive dyskinesia (off-label),Huntington disease (off-label)
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
250 mg orally twice daily
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Reserpine is extensively metabolized in the liver via hydrolysis and glucuronidation; specific CYP enzymes are not well characterized.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
~96% bound to plasma proteins (albumin and lipoproteins).
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Vd 9.4 L/kg, indicating extensive tissue binding (particularly adrenergic neurons, brain, adipose).
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 30–40% due to extensive first-pass metabolism; IM/IV: 100%.
70-90% (oral); 100% (IV).
No specific dose adjustment; use cautiously in severe renal impairment (Cr Cl <30 m L/min) due to risk of hypotension and CNS effects.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to risk of hepatic encephalopathy.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Hypertension: 0.02 mg/kg/day orally divided every 6–12 hours; maximum 0.25 mg/day. Psychosis: not recommended.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 0.05 mg orally once daily; increase slowly due to increased sensitivity and risk of hypotension, sedation, and depression.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
May cause severe depression with risk of suicide (discontinue if depression occurs),Use with caution in patients with history of peptic ulcer disease (increases gastric acid secretion),Use with caution in patients with renal impairment (may reduce renal blood flow),Avoid concomitant use with MAOIs (risk of hypertensive crisis),Electroshock therapy: discontinue reserpine 7-14 days prior,May cause biliary colic in patients with gallstones,May exacerbate arrhythmias in patients with cardiac disease
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to reserpine or any component,History of depression (especially suicidal),Active peptic ulcer disease,Ulcerative colitis,Electroconvulsive therapy (within 7-14 days),Concurrent MAO inhibitor therapy (or within 2 weeks of discontinuation),Pheochromocytoma
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid tyramine-rich foods (aged cheese, cured meats, fermented products, soy sauce, yeast extracts) as reserpine can potentiate pressor responses, leading to hypertensive crisis. Alcohol may increase sedative effects. Grapefruit juice may alter drug metabolism; limit intake.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: risk of neonatal bradycardia, hypotonia, lethargy, and respiratory depression. Use only if benefits outweigh risks.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Reserpine is excreted into breast milk. M/P ratio not established. Risk of infant bradycardia, GI upset, and nasal congestion. Not recommended during breastfeeding.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No specific dose adjustment guidelines. Consider lower starting doses due to increased sensitivity. Monitor maternal blood pressure closely to avoid hypotension.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Serpasil (reserpine) is an antihypertensive and antipsychotic that depletes catecholamines from peripheral sympathetic nerve endings and CNS. Onset is slow (3-6 days) and effects persist for weeks after discontinuation. Monitor for depression, especially in patients with history. Avoid in patients requiring MAOIs due to hypertensive crisis risk. Use with caution in peptic ulcer disease due to increased gastric acid secretion. Bradycardia and nasal congestion are common side effects.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed; do not stop suddenly as blood pressure may rise rapidly.,Report any symptoms of depression, mood changes, or suicidal thoughts immediately.,Avoid alcohol and over-the-counter cold or allergy medications containing decongestants.,May cause drowsiness or dizziness; avoid driving until you know how the drug affects you.,Contact your healthcare provider if you experience slow heartbeat, fainting, or severe stomach pain.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL vs ALDOCLOR-250, answered by our medical review team.
SERPASIL is a Antihypertensive that works by Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL is: Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL is classified as Category C. Reserpine (Serpasil) crosses the placenta. First trimester: no clear evidence of major malformations but risk of fetal bradycardia and hypothermia. Second and third trimesters: ris. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.